


I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on September 11, 2000.


Attorney for Applicant(s)

9/11/2000
Date of Signature

13
10/4/00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: JAMES D. MARKS and PETER AMERSDORFER

Assignee: The Regents of the University of California

Title: THERAPEUTIC MONOCLONAL ANTIBODIES THAT NEUTRALIZE BOTULINUM NEUROTOXINS


Serial No.: 09/144,886

Filing Date: August 31, 1998

Examiner: L. Lee

Art Unit: 1645

Docket No.: M-8951US



COMMISSIONER FOR PATENTS
Washington, D. C. 20231

AMENDMENT

Sir:

In response to the Office Action dated March 10, 2000, Applicants respectfully request reconsideration of the above-identified application in view of the following amendments and remarks. A Change in Correspondence Address and a petition to extend the period of response for three months is enclosed. For the convenience of the Examiner, a list of the pending claims is attached as Appendix I.

In the Claims:

Please cancel claims 44-77 without prejudice.

Please amend claims 1 and 24 as follows:

1. (Once amended) An isolated single-chain antibody that specifically binds to an epitope specifically bound by an antibody expressed by a clone selected from the group consisting of clone S25, clone C25, clone C39, clone 1C6, and clone 1F3, wherein said antibody binds to and neutralizes botulinum neurotoxin type A (BoNT/A).

B'